| Name | Role stated in the filing | Named in |
|---|---|---|
| Balamurali Ambati | Executive Officer, Director | 2026-05-04, 2025-03-17, 2024-01-26, 2023-08-14 |
| Jayakrishna Ambati | Executive Officer, Director | 2026-05-04, 2025-03-17, 2024-01-26, 2023-08-14 |
| Napoleone Ferrara | Director | 2026-05-04, 2025-03-17, 2024-01-26, 2023-08-14 |
| Joon Lee | Director | 2025-03-17, 2024-01-26, 2023-08-14 |
| Mary Weber | Director | 2025-03-17, 2024-01-26, 2023-08-14 |
| Paul Ashton | Executive Officer, Director | 2025-03-17, 2024-01-26, 2023-08-14 |
| Babur Lateef | Director | 2026-05-04 |
| Chaniyilparampu Ramchand | Director | 2026-05-04 |
Want the whole picture on Inflammasome Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Inflammasome Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inflammasome Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Names and roles exactly as the filings list them: executive officers, directors and promoters. Nothing here is inferred, and a filing only lists the people it is required to.